SUBJECT INDEX: VOLUME 43 (2003)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 43 (2003), Number One (January) contains pages 1-130; Number 2 (February), pages 131-296; Number 3 (March), pages 297-420; Number 4 (April), pages 421-548; Number 5 (May), pages 549-684; Number 6 (June), pages 685-838; Number 7 (July), pages 839-988; Number 8 (August), pages 989-1184; Number 9 (September), pages 1185-1342; Number 10 (October), pages 1343-1502; Number 11 (November), pages 1503-1648; and Number 12 (December), pages 1649-1790.

A

AABB 686, 820
ABO blood group
- antigen surface expression 65, 1378
- autoantibodies 1133
- compatibility 328
- A^{el} and A^3 alleles 1138
- enzymatic cleavage of antigens 823
- flow cytometric typing 918
- mismatch 1153
- A transferase expression 656

ABO gene
- histo-blood group mRNA 65
- mutation associated with B_{el} phenotype 1254
- polymorphism screening 428

Absorption of autoantibodies 651
Acrocyanosis 1133
Activation markers 1223
Acute lung injury, transfusion-related
- in ALL 1553
- in animal models 633
- antigen-antibody model of 177
- anti-HLA II antibodies and 185
- due to HNA-3a (5b) alloantibodies 641
- HLA class II antibodies ..... 545(L)
- single-hospital experience 1053

Additive solutions, 12-week RBC storage and 867
Adoptive immunotherapy, dendritic cells in ..... 422(E)
Adult T-cell leukemia 65
African Americans
- DAK antigen and 1394
- donors 598
- mutations in GYPB exon 1738

Age, RBC transfusions after ABMT and 373
AIDS 173
Albumin, serum 1403
Alkaline phosphatase, serum 1414
ALL
- ABH antigenic expression 65
- allogeneic BMT 241, 373
- cord blood transplantation engraftment 1285
- posttransfusion TRALI 1553

Alloantibodies
- absorption 651
- after allogeneic BMT 241
- AIHA 1503
- HNA-3a (5b) 641
- from irradiated cells, regulation of 1295
- maternal 908
- recombinant chimeric production 758
- screening methods, comparison of 72

Allogeneic BMT
- alloantibodies after 241
- hematopoietic mixed chimerism after ..... 1758(L)
- RBC transfusions after 373
- thrombotic microangiopathy and thrombotic thrombocytopenic purpura after 78

Alloimmune thrombocytopenia, fetal 1216
Alloimmunization 173, 765
American Society for Apheresis 686, 820
American University of Beirut-Medial Center 1672
Amicus blood cell separators 814, 1423
AML 373, 945
Amotosalen 1481
Anaphylaxis, IVIG therapy 1460
Anemia
- bloodless medicine and 668
- fetal, in anti-K hemolytic disease ..... 115(L)
- functional recovery from surgery and 1717
- isovolemic, heart rate and 235

Anesthesia, bloodless medicine and 668
Animal models
- acute lung injury from stored platelets 633
- extending time period for platelet storage ..... 983(L)
- irradiation effects on immune response 576
- posttransfusion RBC volume and survival 1366
- vCJD and GSS strain infectivity 1687

Antibodies. *See also specific antibodies*
- diclofenac-induced 345
- Dombrock 107
- to high-frequency antigens 1563
- to low incidence antigens 844, 939
- passive transfer 1460
- platelet, detection of ..... 835(L)
- reactivity after prewarm technique 1611

Anti-c 241
Anti-D
- development in D- patients receiving D+ RBCs 893
- flow cytometric typing 918
- immunization 1248
- with naïve L chains 246

Anti-DAK 1394
Anti-Di^b complicated pregnancy ..... 1642(L)
Anti-E 241
Antigens. *See* RBC antigens
Antiglobulin test 844
Anti-HBc-reactive blood donors, in India 1442
Anti-HBc-reactive units 696
Anti-HCV screening
- detection of carriers 953
- with HCV core antigen assay 1067

Anti-HIV screening 1428
Anti-HLA 663
Anti-HLA-A2 687
Anti-HLA-A28 687
Anti-HLA-B7 687
Anti-HLA II antibodies, TRALI and 185
Anti-HPA-1a 350
Anti-HPA-3A 1398
Anti-Jk3 685
Anti-Js^b 758
Anti-K hemolytic disease, fetal anemia in ..... 115(L)
Anti-RANTES 1038
Anti-WBC immunoglobulins 633
Apheresis
- A antigen surface expression on PLTs 1378
- complications during 736
- DDAVP-stimulated for VWD 1514
- pediatric, radial artery for 254
- plasma, residual cell content in 1522
- plasma quality and 1223
- platelet bacterial surveillance 974
- platelet storage limits 143

Apheresis systems 814, 1223, 1309
Aplastic anemia 241
Apoptosis 526, 857
Apoptotic markers, in stored platelets 857
Applied muscle tension, to reduce donor symptoms 1269

APTT 563, 1238
Arab thalassemia patients 1604
Arm soreness, after whole-blood donation 598
Artificial oxygen carriers 280, 668
Aseptic meningitis, from IVIG therapy 1460
Aseptic technique, PLT bacterial contamination and 974
A transferase, N-truncated 656
Austria, HCV NAT in ..... 834(L)
Autoanti-B 1133
Autoantibody absorption 651
Autograft, second 259
Autoimmune hemolytic anemia, least compatible units for 1503
Autoimmune thrombocytopenic purpura 1121
Autoimmunization 1604
Autologous BMT
  early neutrophil engraftment 614
  uncontrolled-rate freezing 42
Autologous placental blood transfusion 1210
Autologous transfusion devices, complement activation 395
Automated systems
  for anti-HCV and HCV core antigen assay 1067
  for apheresis, plasma protein composition and 1223
  for flow cytometric blood typing 918
  PCR-ELISA for blood grouping 1126
  for PLT monitoring 974

B

Babesiosis S8:3
Bacterial contamination
  culture method for preventing 1047
  PBPC products 1587
  transfusion risks S8:3
Bacterial detection system, for platelet concentrates, 1374 1276
Bacterial risk estimation, with extended PLT shelf life 1047
Barcode use, blood transfusion safety and 1200
Basophil chemotaxis assay 1038
B-cell non-Hodgkin's lymphoma 614
B_{el} phenotype 1254
Bernard-Soulier syndrome 563
Biologic response modifiers, platelet-derived 1038
Biotinylated RBCs 1168
Bleeding, as platelet transfusion outcome measures 742
Bleeding time 563
Blood availability S8:3
Blood bank automation S8:3
Blood cell separators, comparative efficacy of 1423
Blood collection centers S8:3
Blood collection safety S8:3
Blood components. *See also specific blood components*
  reimbursement S8:3
  West Nile virus transmission 992, 1007, 1018, 1023, 1029
Blood credits, as blood donation incentive 7
Blood delivery S8:3
Blood donation
  allogeneic, by hemochromatosis patients 1538
  AMT in reducing blood donation-related symptoms 1269
  body weight and 1084
  frozen preoperative autologous 476
  HCV and HIV-RNA duplex assay 215
  HCV screening 713, 953, 1067
  HIV antibody screening 1428
  incentives 7
  from men who have sex with men 25
  patterns, increasing blood availability 591
  in Scotland 1060
  seroreactive 1433
  transmission risk for West Nile virus 1007
  trends 1634
  unrelated umbilical cord 604
  volunteer programs 273
Blood donation-related symptoms, reducing 1269
Blood donation site, prevalence of transfusion-transmissible viral infections 705
Blood group antibody identification, DNA-based assays 1748
Blood group antigens
  DNA-based assays 1748, 1754
  passive transfer 1460
Blood group incompatibility 273
Bloodless medicine 550, 668
Blood pressure, after blood donation 1269
Blood recipients, D-mismatched RBCs 173
Blood-related organizations S8:3
Blood safety. *See* Safety
Blood storage. *See* Storage
Blood substitutes 280, 668, 823, S8:3
Blood supply
  federal regulation of S8:3
  precautionary principles ..... 840(E)
Blood transfusion
  activation of CMV replication 1351
  allogeneic, mortality and 963
  anti-D development in D- patients receiving D+ RBCs 893
  autologous placental 1210
  buffy coat-depleted 765
  costs S8:3
  of D-mismatched RBCs 173
  HGV/GB virus C transmission 1558
  hip fracture outcomes and 1358
  for liver transplant surgery 322
  risk perception 772, 779
Blood typing, by flow cytometry 918
Blood utilization committee, resurgence of 998
Body weight, vasavagal reactions and 1084
Bone marrow transplantation. *See* Allogeneic BMT; Autologous BMT
Book reviews 986, 1338, 1498, 1644, 1652
Bovine spongiform encephalopathy 1687, 1706
Brazil, prevalence of Chagas' disease in first-time donors 853
Buffy coat-depleted blood transfusion 765

C

Calcium carbonate supplementation, in plateletpheresis 1403, 1414
Calcium excretion, calcium supplementation in plateletpheresis 1414
Calcium-gluconate, reduction of citrate-related side effects 1615
Canada, coagulation factor concentrate tracking system 556
Caucasian donors 598
CD177 antibodies, in pregnancy 357
CD34+CD8– 383
CD14+ cells 488, 1309
CD34+ cells
  collection 1423
  cord blood, expansibility of 383
  early neutrophil engraftment and 614
  G-CSF-mobilized 1575
  transmigration 1575
  yield after high-dose chemotherapy and autografting 259
  yield prediction 495, 622
CD62P surface expression ..... 2(E), 1230
Cell death, in stored platelets 526
Cell processor, for umbilical cord blood 806
Cell separators
  collection of single-donor PLTs 1107
  modified 481
  for PBPC collection 58, 814, 1423
Cellular engineering 823
Cephalosporin, thrombotic thrombocytopenic purpura after 1317
ceRT 1248
CFU-GM 614
CFUs, recovery from cryopreserved cord blood 265
Chagas' disease
  ensuring blood safety S8:3
  improved serodiagnostic test 91
  prevalence 853
Chemiluminescent immunoassay
  analyzer for anti-HCV and HCV core antigen 1067
  biologic false reactivity 584

Chemotherapy
filgrastim dosage for PBPC mobilization with 50
leukapheresis after 259
stem cell mobilization and 622
Chimerism-associated hemolysis 1449
Chinese, Jk(a-b-) and Kidd blood group genotypes ..... 289(L)
Chlamydia pneumoniae 552, 646
Cholesterol screening, as blood donation incentive 7
Chronic myeloid leukemia 241
Circulatory arrest, during PBPC apheresis 736
Circulatory reactions 1096
Citrate-induced symptoms, reducing 1403, 1414
Civil disaster experiences, blood use in 1622
CJD ..... 425(E), 1687, 1690, S8:3
Clean room conditions 1587
Closed system, for umbilical cord blood processing 806
Closed washing system, for frozen RBCs 157
CML
cord blood transplantation engraftment 1285
RBC transfusions after allogeneic BMT 373
CMV
absence of activation 1351
blood safety and S8:3
in donors ..... 314, 1493(L)
prevention of transmission 302
transmission risk 309
Coagulation factor concentrates 556
Coagulation factors
freeze-thawing of FFP and 1238
safety of methylene blue-treated FFP 1322
Cobe Spectra Apheresis system 481
Cobra venom factor 395
Cold agglutinin disease 839, 1185
Cold antibodies, reactivity after prewarm technique 1611
Column agglutination technology 651, 918
Compatibility testing
in autoimmune hemolytic anemia 1503
blood safety and S8:3
missing antibodies to low incidence antigens 844
Complement activation, by autologous transfusion devices 395
Computer-assisted self-administration interview 165
COM.TEC cell separator 1107
Congenital antithrombin deficiency 390
Congenital platelet TxA_2 receptor abnormality 563
Continuous processing, saline washing and centrifugation
complement activation 395
Contracted notification service 799
Controlled-rate freezing 42, 1303
Cord blood
automated processing 806
cryopreservation, DMSO with trehalose for 265
future developments 823
short-term liquid storage 626
simple controlled-rate freezing 1303
transplantation 383, 1285
unrelated donation, attitudes on 604
in utero *vs.* ex utero collection ..... 1174(L)
Cost, of producing safe blood supply S8:3
Cost-effectiveness analysis, of expanded HBV testing protocols 192
Creatinine, serum 1403
Cromer blood group system 340
Crossmatching, antibodies to low incidence antigens and 844, 939
Cross-reactive group 753
Cryoprecipitate, from single donor 1514
Cryopreservation
breakage of RBCs 411
controlled-rate freezing 42
of cord blood 265, 1303
dendritic cell 488
effects on 42-day-old AS-3 RBCs 1527
G-CSF-mobilized PBPCs 1575
preoperative autologous blood donation 476
simple controlled-rate freezing 1303
WBC reduction in cryopreserved RBC units 517
CS-3000+ blood cell separators 1423
Cyclosporine A 78

D

DAK 1394
D antigen typing 1248
DAT, negative or weak ..... 1640(L)
DDAVP 563, 1514
Decay-accelerating factor 340
DEHP exposure, from PVC devices 1115
Delayed hemolytic anemia 241
Dendritic cells
in adoptive immunotherapy ..... 422(E)
cryopreservation 488
culture 1309
generation 481
Diclofenac-induced antibodies 345
Di(2-ethylhexyl)phthalate exposure, during plateletpheresis 1115
1,25-Dihydroxyvitamin D 1414
Disasters, blood use during 1622
DMSO
dendritic cell cryopreservation 488
PLT storage 1162
with trehalose for cord blood cryopreservation 265
wash-out, CBT recovery and 1285
DNA-based assays. *See* Nucleic acid testing
Dombrock blood group system ..... 107, 1495(L)
Donors
A_1, A antigen surface expression on PLTs 1378
adverse effects after whole-blood donation 598
allogeneic 1295, 1343
anti-HBc-reactive 1442
biologic false reactivity 584
body weight, vasovagal reactions and 1084
citrate-induced symptoms during plateletpheresis 1403
CMV DNA detection ..... 314, 1493(L)
EDRF transcripts in 1706
exposure to plasticizer during plateletpheresis 1115
extracorporeal volume 1096
first-time 853, 1084
G-CSF-induced spleen size changes 609
Hb screening 306, 400
HBV DNA detection 696
HCV ..... 116(L), 541, 953, 1452
HHV-8 seroprevalence, viral load and 85
HIV infection detected by HIV NAT 848
HNA-3a (5b) alloantibodies 641
human herpesvirus 8 seroprevalence in 1260
lapsed interval lengths 17
payment of 273
perceptions of health history screening 165
plasmapheresis, iron metabolism in 405
platelet, from D+ to D– ..... 1759(L)
Portuguese, Dombruck alleles genotyping by RT-PCR ..... 1495(L)
quality, platelet recovery and 328
recruitment 1596, 1634
restrictions 273
Scottish, enterovirus viremia in 1060
screening educational materials 1075
single-dedicated cryoprecipitate 1514
telomere length of PBLs 1089
testing 823
transfusion-transmitted West Nile virus infection 1018
younger, risk profile of 1596
Donor transmission
Creutzfeldt-Jakob disease ..... 425(E)
hepatitis A 536
D- patients, receiving D+ RBCs 893
DRGs, blood-intensive S8:3
Drug-dependent antibodies 345
Drug-induced immune hemolytic anemia ..... 1640(L)

E

EIA 1433, 1452
ELISA
- alloantibody screening 72
- HCV carrier detection 953
- HCV core antigen ..... 118(L)
- HCV 3.0 *vs.* 2.0 1452
- quantitative, for anti-HPA-1a 350

elutriation device, single-use 481
Endothelial cells
- cellular prone protein ..... 677(L), 679(L), 680(L)
- RBC adherence, WBC reduction and irradiation effects on 151

Engraftment
- cord blood transplantation 1285
- potshot CD34+ cells and 878

Enterovirus infections, in Scottish blood donors 1060
Enzyme treatment, of platelets for antibody detection ..... 835(L)
Error management, evolution of 1330
Erythroid differentiation-related factor 1706
Erythromelaglia, erroneous ..... 1336(L)
Erythropoeitin, bloodless medicine and 668
Europe 459
European Union 192
Expansion protocols 383
Extracorporeal volume, in plasmapheresis 1096

F

Fatigue, donor 598
FDA
- evaluation of pathogen reduction technology ..... 1347(E)
- HCV look back notification 799
- quality management evolution and 1330

Female partners, of male donors who have had sex with men 25
Fetal alloimmune thrombocytopenia 1216
Fetal anemia, in anti-K hemolytic disease ..... 115(L)
Fetal RBCs, in maternal blood ..... 416(L)
FFP
- in liver transplant surgery 322
- methylene blue-treated 1238, 1322
- repeat freeze-thawing 873
- WBC-reduced, hepatitis A transmission 536

Fibrinogen 568, 873
Filgrastim 50, 495
Filtration 765
F IX 470, 873
FK-506 78
Flow cytometry
- A antigen surface expression on PLTs 1378
- for blood typing 918
- fetal RBCs in maternal blood ..... 416(L)
- glycophorin quantification 1145

FlowPRA assays, anti-HLA II detection 185
Fludarabine, transfusion-associated GVHD 1667
France, military blood banking 1622
Freeze-thawing 873, 1238
Freeze-thaw-wash process 157
FUT3, single-nucleotide polymorphism ..... 1760(L)
FUT1(H) gene 65
FVII 873
FVIII 470, 563
FVIII inhibitors 1508
FX 873
FXII 1238

G

Gamma-irradiation, immune response and 576
G-CSF
- adverse effects 609, 1343
- transmigration of mobilized PBPCs 1575

Gender differences
- in citrate-induced symptoms during plateletpheresis 1403
- RBC transfusions after allogeneic BMT 373

Gene therapy 823
Genotyping
- of Dombruck alleles in Portuguese blood donors by RT-PCR ..... 1495(L)
- human platelet antigens 445
- PCR-ELISA 1126
- regulation of alloantibodies in UVB-irradiated cells 1295

Gerstmann-Sträussler-Scheinker disease 1687
Glanzmann's thromboasthenia 563, 885
Glycerol 411
Glycophorin A 1145
Glycophorin B 1145, 1738, 1746
Good manufacturing practices 1330
GPIIb/IIa expression, in stored platelets 1230
Great Britain, military blood banking 1622
Greece, HTLV-I and HTLV-II in ..... 1641(L)
Growth factors 622
GUTI antigen 340
GVHD, transfusion-associated
- after fludarabine 1667, 1669
- blood safety and S8:3
- IVIG therapy 1460
- radiation effects on 502
- 10 year experience 1672

GYPB exon 1738

H

H antigen 65
Hb
- bloodless medicine 668
- heart rate and 235
- hip fracture repair recovery 1717
- RBC transfusions after allogeneic BMT 373
- screening 306, 400
- serial plasmapheresis donors and 405
- solutions 823

Hb oxygen carriers 280
HBsAg
- biologic false reactivity 584
- lapsed interval lengths 17
- screening assays 202, 788

HBV
- absence after allogeneic RBC transfusion 451
- in anti-HBc-reactive units 696
- in plasma pools for fractionation ..... 1763(L)
- transfusion-associated 1442

HBV NAT
- comparative assay sensitivity 788
- cost-effectiveness 192, 721

H chains 246
Hct
- immediate *vs.* delayed cord clamping 1168
- thrombocytopenia treatment ..... 1761(L)

HCV
- absence after allogeneic RBC transfusion 451
- carriers 953
- diagnosis 958
- lapsed interval lengths 17
- lookback notification 799
- low-level viremia ..... 1173(L)
- transmission via transfusion S8:3
- viral load in donors 541, 1433

HCV core antigen assay
- with anti-HCV test 1067
- carrier detection 953
- ELISA ..... 118(L)
- Trak-C 958

HCV NAT
- in Austria ..... 834(L)
- biologic false reactivity 584
- carrier detection 953
- cost-effectiveness 721

donor screening ..... 116(L), 202
HCV 3.0 *vs.* 2.0 EIA 1452
minipool testing 215
RNA 215, 958
RT-PCR minipool ..... 118(L), 713
sequential strategies for 226
viral load before seroconversion 541
Health history screening 35, 165
Health Portability and Accountability Act ..... 1186(E)
He antigen 1738, 1744
Heart rate 235, 1269
Heart transplantation, frozen preoperative autologous blood donation 476
Hematologic recovery
after autologous PBPC transplantation 878
harvesting second autograft during 259
uncontrolled-rate freezing and 42
Hematoma, in donors 598
Hematopoietic growth factors 622, 823
Hematopoietic mixed chimerism, after allogeneic BMT ..... 1758(L)
Hematopoietic stem cells
turnover, PBL telomere length and 1089
yield predictions 622
Hematopoietic stem cell transplantation, ABO mismatched 1153
Hemochromatosis, allogeneic blood donation and 1538
Hemofiltration, complement activation 395
Hemolink 280
Hemolysis, chimerism-associated 1449
Hemolytic anemia, cold agglutinin titer and 1133
Hemolytic disease, fetal ..... 115(L), 119(L)
Hemolytic disease of newborn, after maternal in vitro fertilization ..... 288(L)
Hemolytic transfusion reactions
antibodies to low incidence antigens 844
caused by chimeric RBCs 1449
secondary to HLA alloimmunization 753
Hemolytic uremic syndrome, plasma exchange complications ..... 415(L)
Hemophilia A 470
Hemophilia B 470
Hemostatic agents, recombinant FVIIA 1711
Hepatitis, transfusion-related transmission 536, S8:3
Hepatitis B surface antigenemia, transient ..... 545(L)
Hepatitis G virus S8:3
Herpes viruses S8:3
HES 488
HGV/GB virus C transmission 1558
HHV-8 seroprevalence, viral load in health donors and 85
High-dose chemotherapy, leukapheresis after 259
High-glycerol method, RBC stability after thawing 157
Hip arthroplasty
blood management 459
hemoglobin levels and 1739, 1745
outcomes, blood transfusion and 1358
HIPAA, security under ..... 1186(E)
HIV
absence after allogeneic RBC transfusion 451
activation of CMV replication in 1351
lapsed interval lengths 17
prevalence in blood donors in Thailand 731
risk, MSM blood donors and 25
transmission via transfusion S8:3
HIV NAT
antibody screening and 1428
biologic false reactivity 584
cost-effectiveness 721
detection by HIV RNA testing 848
minipool testing 215
new, impact of 202
sequential strategies 226
HLA-A24/A1 matrix protein pp65$_{141-159}$ 1567
HLA antibodies
alloimmunization 663, 753, 765
class II ..... 545(L)
hemolytic transfusion reactions 687
neonatal alloimmune thrombocytopenia and 908
HLA class I antigens 177
Hospital
blood supply costs S8:3
TRALI experience 1053
transfusion safety in 1190
HPA-3 system 1398
HTLV
absence after allogeneic RBC transfusion 451
biologic false reactivity 584
screening assays, sequential strategies for 226
in southwestern Greece ..... 1641(L)
transmission via transfusion S8:3
Human herpesvirus 8 ..... 451, 1260
Human neutrophil antigen-3a (5b) alloantibodies 641
Human neutrophil antigen-2a expression, in pregnancy 357
Human platelet antigens 445, 1398
Hyperlipidemia, secondary to nephrotic syndrome 421
Hypogammaglobulinemia, IVIG for 1460
Hypotension, from IVIG therapy 1460

I

IgG
CMV antibodies ..... 1493(L)
recombinant chimeric production of 758
IgM
CMV antibodies ..... 1493(L)
recombinant chimeric production of 758
Immigration, paternity testing ..... 982(L)
Immune hemolytic anemia, drug-induced ..... 345, 1640(L)
Immune response, irradiation effects on 576
Immunoabsorption, for FVIII inhibitor removal 1508
Immunodeficiencies 1460
Immunoglobulin, PLT-associated, increased ..... 1494(L)
Immunohematology testing, by flow cytometry 918
Immunomodulation 823, 1460
INACTINE process, for pathogen reduction 135, 1386
India, anti-HBc-reactive blood donors 1442
Indirect immunofluorescence method 72
Injection drug use, younger donors and 1596
INTERCEPT program 1481
Interlaboratory comparisons, HHV-8 DNA in donors 1260
International Red Cross, blood use in disaster and war 1622
Intrauterine transfusions, platelet 1216
Intravascular hemolysis, after chimeric RBC unit transfusion 1449
In vitro fertilization, hemolytic disease of newborn and ..... 288(L)
Iron
metabolism, in serial plasmapheresis donors 405
supplementation 405, 668
Irradiation, RBC adherence to vascular endothelia and 151
Isovolemic anemia, heart rate and 235
Israel, military blood banking 1622
Italy, HIV infection detected by HIV NAT in blood donor 848
IVIG therapy, adverse effects 1460

J

JCAHO 998
Jehovah's Witnesses, bloodless medicine and 550, 668
Jk(a-b-) ..... 289(L), 685

K

Kaposi's sarcoma-associated herpesvirus 1260
Kawasaki, IVIG therapy 1460
Kell blood group system
anti-K hemolytic disease, fetal anemia in ..... 115(L)
surface protein, diminished expression 1121
Kidd blood group system ..... 289(L), 685
Kinship studies ..... 979, 982(L)
Knee arthroplasty, blood management 459
Kuwait Central Blood Bank 1604

L

Large-volume leukapheresis, reduction of citrate-related side effects 1615
Laser-assisted optical rotational cell analyzer, RBC deformability measurements 1533
Laypeople perception, of blood transfusion risk 772
L chains 246
Lebanon, military blood banking 1622
Leukapheresis
  after high-dose chemotherapy 259
  comparative efficacy of blood cell separators 1423
  comparison of two computerized PBPC systems 58
  large-volume 495
Leukoreduction. *See* WBC reduction
Leukotriene B_4 633
Lewis blood group, null-phenotype ..... 1760(L)
LISS 651
Liver transplant surgery 322
LOCR 440
Long-term hematopoietic reconstitution 614
Low-birthweight infants 663
Low-glycerol method, RBC stability after thawing 157
Low-incidence antigens 844, 939, 1394
LP-MNC software 58
LP-PBSC-Lym software 58
Lutheran blood group 1729, 1736
Lymphocyte immunofluorescence test 72
Lymphocytes
  irradiated 502
  viability after freezing 488
Lymphocytotoxicity assay 72, 185

M

Magnesium 1403, 1414
Malaria S8:3
Male-to-male sex, younger donors and 1596
Maternal blood, quantitation of fetal RBCs in ..... 416(L)
Matrix protein $pp65_{341-350}$ 1567
Mayo Clinic 476
McLeod phenotype 928
Medicaid S8:3
MedPAC analysis of blood costs S8:3
Melting curve analysis 445
Menstruation 405
Men who have had sex with men 25, 730
Meryman-Hornblower freezing method 411
Mesenchymal stem cells 1
Methylene blue photoinactivation 568, 1238, 1322
β_2-Microglobulin mRNA 65
Military blood banking 1622
Minipool screening
  cost-effectiveness 721
  enterovirus viremia in donors 1060
  HCV RNA 713
  HIV 1428
  RT-PCR (HCV NAT) ..... 118(L)
  vs. individual screening 215
  vs. single-donation testing 1433
Mismatch, ABO 1153
Mix-ELISA, Chagas' disease diagnosis 91
MNCs 66, 488, 814
Mobilization 495, 622, 736
Model virus data, in predicting plasma derivative safety 1023
Molecular genetic analysis
  A^{el} and A^3 alleles 1138
  P^k gene 899
Monitoring, United States blood supply ..... 364, 1639(L)
Monoclonal antibody-specific immobilization, of platelet antigens assay 72
Monocyte
  activation, TRALI and 177
  collection 1309
  enrichment 481
Morbidity, transplant-related 1153
Mortality, transplant-related
  ABO mismatch and 1153
  allogeneic WBC-reduced 963
  hip fracture and 1358
MP4 509
Multiple-component collection system 1695, 1704
Multiple transfusions, for low-birthweight infants 663
Mutations 928, 1121, 1254
Myelodysplastic syndrome, cord blood transplantation engraftment 1285
Myeloid growth factors 823

N

NAT. *See* Nucleic acid testing
National Blood Data Resource Center, monitoring United States blood supply 364
National Blood Service monitoring ..... 299, 1639(L)
NAT-negative blood, transfusion-transmitted infection risk in ..... 830(L)
Nausea, in donors 598
Naval Blood Research Laboratory freezing method 411
NB1 expression, in pregnancy 357
Necrotizing enterocolitis 1210
Neonatal alloimmune thrombocytopenia 908, 1398
Neonates
  alloimmunization 663
  autologous placental blood transfusion 1210
  low-birthweight 663
  preterm, immediate *vs.* delayed cord clamping 1168
Neurocardiogenic syncope 736
Neutrophil engraftment, following autologous BMT 614
New York State, hemophilia in 470
Nonhemolytic transfusion reactions 1038
Nonmyeloablative conditioning 1153
Non-WBC-reduced RBC units 1351
Nucleic acid testing
  blood group antigen/antibody identification 1748
  blood supply safety and S8:3
  cost-effectiveness 721
  detection of acute HCV infection ..... 116(L)
  HBV 192, 721, 788
  HCV. *See* HCV NAT
  HIV. *See* HIV NAT
  low-level HCV viremia missed by ..... 1173(L)
  minipool *vs.* individual testing 215
  prevention of transfusion-acquired CMV infection 302
NUTRICEL (AS-3) 1527

O

Obituary, of Albert E.G. Kreutzwendedich von dem Borne 1340
Objective structured clinical examination 35
Off-label uses, for IVIG therapy 1460
Open heart surgery
  allogeneic blood transfusion, mortality and 963
  HGV/GB virus C transmission 1558
Orthopedic surgery, elective 459
Osteocalcin, calcium supplementation in plateletpheresis and 1414
OSTHEO study 459
Oxygen affinity 509
Oxygen carriers, Hb-based 280, 668
Oxygen percentage, bacterial detection system PLTs and 1276

P

Parasitic-borne infections S8:3
Parathyroid hormone 1414
Parentage tests ..... 979, 982(L)
Paresthesias, reducing 1403
Passenger lymphocyte syndrome 241
Paternity testing ..... 979, 982(L)

Pathogen inactivation
of PLTs ... 1481
of RBCs ... 1386
Pathogen reduction
FDA evaluation ... 1347(E)
in future ... 823
novel process ... 135
safety of methylene blue-treated FFP ... 1322
Patient identification system, for transfusion safety ... 1200
PBPC collection
after high-dose chemotherapy ... 259
cell separators for ... 58, 814
circulatory arrest during ... 736
computerized, comparison of programs for ... 58
pediatric, percutaneous radial artery catheter for ... 254
reduction of citrate-related side effects ... 1615
yields, during large-volume leukapheresis ... 495
PBPC mobilization ... 50
PBPCs
bacterial contamination of ... 1587
expression levels of histo-blood group mRNA ... 65
G-CSF-induced spleen size changes ... 609
transplantation ... 814, 878
PCR. *See also* RT-PCR
ABO gene polymorphism screening ... 428
CMV DNA detection ... 314
HBV DNA ... 1442
HCV carrier detection ... 953
HHV-8 ... 1260
PCR-ELISA ... 1126
PCR-RFLP ... 335, 340
PCR-SSP method ... 335
PEG-Hb conjugate ... 509
PEN110 reproductive toxicology studies ... 1386
Perception of blood transfusion risk ... 772, 779
Percutaneous radial artery catheter, for pediatric PBPC collection ... 254
Peripheral blood leukocytes, telomere length ... 1089
Phenotypes
B_{el} ... 1254
A^{el} and A^3 alleles ... 1138
fetal RBCs in maternal blood ... 416(L)
p ... 899
S-s-$U+^{var}$ ... 1738
Photochemical pathogen inactivation ... 1481
Photodynamic treatment, RBC deformability and ... 1533
Photoinactivaton ... 1238
Phototoxicity ... 1481
Physician perception, of blood transfusion risk ... 772
Physicians for the Advancement of Transfusion Medicine ... 1344
P^k gene, molecular analysis ... 899
Placental blood transfusion, autologous ... 1210
Plasma
derivatives, safety of ... 1023
pathogen inactivation of blood components ... 823
product terminology, standard ... 983(L)
pathogen reduction technology for ... S8:3
Plasma exchange
complications ... 415(L)
DDAVP-stimulated ... 1514
Plasmapheresis
extracorporeal volume ... 1096
residual cell content and ... 1522
serial ... 405
Plasmodium falciparum, RBC exchange and ... 549
Platelet aggregation, storage effects on ... 1230
Platelet concentrates
bacterial detection system for ... 1276
extended shelf life, bacterial risk estimation ... 1047
in-line whole-blood filter ... 1723
metabolic stress, reversibility of ... 1230
monitoring of bacterial contamination ... 974
seven-day storage ... 1374
storage limits ... 143
swirling ... 2(E)
WBC-reduced single-donor ... 1107
Platelet-derived biologic response modifiers ... 1038
Platelet disorders ... 885
Platelet donation, telomere length of PBLs ... 1089
Platelet growth factors ... 823
Platelet immunofluorescence test ... 72
Platelet mitochondrial transmembrane potential ... 526
Platelet-poor plasma ... 1162
Platelet-rich plasma methods ... 1723
Platelets
antibodies against ... 345
A antigen surface expression ... 1378
artificial ... 823
enzyme treatment for antibody detection ... 835(L)
high residual ... 1309
irradiated ... 502
pathogen inactivation of blood components ... 823
PRTs for ... S8:3
toxicology assessment and ... 1481
Platelet storage
apoptotic markers and ... 857
extending time period for ... 983(L)
PLT-associated immunoglobulin increases ... 1494(L)
RANTES and ... 1038
reversibility of metabolic stress ... 1230
seven-day ... 143, 1374
temperature effects ... 1162
Platelet transfusion
acute lung injury in animal model ... 633
from D+ to D– donors with hematologic disease ... 1759(L)
intrauterine ... 1216
nonhemolytic transfusion reactions ... 1038
outcome measures ... 742
reactions ... 291(L), 1545
recovery after ... 328
threshold ... 691
thrombotic thrombocytopenic purpura and ... 829(L)
Point mutations ... 1121
Polymorphisms ... 335
Portable multiple-component collection system ... 1695
Portuguese blood donors, by RT-PCR Dombruck alleles genotyping ... 1495(L)
Postthaw CD34+ cells, engraftment and ... 878
Posttransfusion
hepatitis B ... 192
platelet survival & function, predicting ... 2(E)
survival ... 418(L), 1366
Power of exclusion in first-degree relatives ... 979
p phenotype ... 899
Prediction
of plasma derivative safety ... 1023
of posttransfusion platelet survival & function ... 2(E)
Pregnancy
anti-Di^b complicated ... 681(L), 1642(L)
HNA-3a (5b) alloantibodies ... 641
NB1 expression ... 357
Preoperative autologous blood donation ... 476, 668
Preterm infants ... 663, 1168
Prewarm technique, antibody reactivity after ... 1611
Prion disease risk ... 1460
Prion protein, cellular ... 677(L), 679(L), 680(L)
PRISM HCV antibody detection ... 1067
Privacy, under HIPAA ... 1186(E)
Private health insurance ... S8:3
Procoagulant action ... 885
Producer price index ... S8:3
Programmed cell death. *See* Apoptosis
Prospective payment system reimbursement ... S8:3

Protein composition, of plasma obtained by automatic apheresis 1223
Prothrombin time
DDAVP and 563
freeze-thawing and 873, 1238
PRP 1162
PRT S8:3
PSA screening, as blood donation incentive 7
Pseudomonas fluorescens outgrowth prevention 135
Pseudomonas putida outgrowth prevention 135
Psoralen plus UVA 576
PVC devices, DEHP exposure from 1115

Q

Quality management, evolution of 1330

R

Radial artery, for pediatric apheresis 254
Radiation effects, on blood cell rheology 502
Radioisotope methods for RBC volume and survival measurement 1366
RANTES 1038
RBC adherence 151
RBC alloantibody testing 918
RBC alloimmunization 945, 1604
RBC antigens
blood group 823
high-frequency, antibodies to 1563
LOCR 440
low-incidence 939, 1394
site quantification 1145
RBC component therapy 322
RBC exchange, *Plasmodium falciparum* and 549
RBC growth factors 823
RBC immunization 765
RBC lysis resistance 685
RBCs
antigen site quantification 1145
from autologous placental blood transfusion 1210
deformability 1533
D-mismatched 173
frozen, breakage of 411
K_{mod} phenotype 1121
leukoreduced, collection of 1695
PRTs for S8:3
survival 687
RBC transfusion
after allogeneic BMT 373
allogeneic 451
requirements after allogeneic marrow transplant 373
RBC units
buffy coat-depleted 646
cryopreserved, WBC reduction in 517
leukoreduced, collection of 1695
pathogen inactivation 823
stability after thawing, high- *vs.* low-glycerol method for 157
twelve-week storage 867
WBC-filtered, residual cells in 98
WBC-reduced 536, 1351, 1695
RBC volume
immediate *vs.* delayed cord clamping 1168
radioisotope *vs.* nonradioisotope measurement methods 1366
Recombinant antithrombin, for hereditary AT deficiency during surgery 390390
Recombinant chimeric alloantibody production 758
Recombinant FVIIa 885, 1711, 1716
Reimbursement, blood component S8:3
Rejuvenation, effects on 42-day-old AS-3 RBCs 1527
REJUVESOL treatment 1527
Renal failure, from IVIG therapy 1460
Reproductive toxicology studies, PEN110 chemistry for 1386
Retrovirus Epidemiology Donor Study 7, 17, 165, 1596
Rh blood group system
anti-D immunization 893, 1248
antigens 440, 823
antigen typing 1248
D+ ..... 1759(L)
D zygosity testing 335
low-incidence antigen 1394
RHCE allele 1248
Rheology 502
Rhesus boxes 335
rHuEPO, for anti-Di^b pregnancy ..... 681(L)
Risk assessment 1481
Risk-benefit analysis
MSM blood donation 25
pathogen-reduced transfusion products ..... 1347(E)
Risk profile, of younger donors 1596
Ristocetin cofactor 563
rRHu G-CSF mobilization 736
RT-PCR
Dombruck alleles genotyping ..... 1495(L)
HCV RNA 215, 713
minipool *vs.* individual screening 1433

S

Safety
autologous placental blood transfusion 1210
barcode use and 1200
in hospital 1190
improvements S8:3
methylene blue-treated FFP 1322
of pathogen-reduced transfusion products ..... 1347(E)
of plasma derivatives 1023
of S/D-treated plasma ..... 1176(L)
Scotland, blood donors in 1060
Screening
for blood-borne viruses 1428
for Chagas' disease 853
educational materials, donor understanding of 1075
new viral marker, impact of 202
sequential immunoassays before immunoblot testing 226
S/D-treated plasma ..... 1176(L)
Security, under HIPAA ..... 1186(E)
SEN-V S8:3
Seroconversion
Chlamydia pneumonia 646
CMV 309
HCV 541
West Nile virus 1018
Serologic assays
Chagas' disease 91
human herpesvirus 8 1260
Serum hyperviscosity, in Waldenstrom's macroglobulinemia 989
Short tandem repeat sequences, in paternity testing ..... 979, 982(L)
Single donation
collection of two units of leukoreduced RBCs 1695
platelet concentrates 1107
Single-nucleotide polymorphism, Lewis blood group null-phenotype ..... 1760(L)
Spain
HCV screening 713
military blood banking 1622
Spectra 814
Spherocytes 576
Spleen, G-CSF-induced size changes 609
St. Louis encephalitis viruses 992
Sterile connection device, PLT bacterial contamination 974
Steroid use, younger donors and 1596
Storage
A antigen surface expression on PLTs 1378
cryopreserved dendritic cells 488

extended shelf life for platelet concentrate 1047
G-CSF-mobilized PBPCs 1575
length 1162
platelet. *See* Platelet storage
RBC adherence, WBC reduction and irradiation effects on 151
short-term liquid, for umbilical cord blood 626
temperature 1162
TRALI in animal models 633
twelve-week RBC 867
Surgery
bloodless 668
effect of transfusion on hip fracture outcomes 1358
recombinant antithrombin for hereditary AT deficiency 390
recovery, hemoglobin levels and 1717
Switzerland, unrelated umbilical cord blood banking 604
Systemic lupus erythematosus 1667

T

Tacrolimus 78
Taiwanese
ABO gene mutation associated with B_{el} phenotype 1254
A^{el} and A^{y} alleles 1138
Telomere length, of PBLs 1089
Temperature for platelet storage, apoptosis and 857
Thailand, HIV blood donors in 731
Thalassemia major 1604
Therapeutic apheresis 820
Thrombocytopenia
apheresis-induced 814
fetal alloimmune 1216
platelet transfusion outcome measures 742
recombinant FVIIa 885
treatment, hematocrit and ..... 1761(L)
Thromboembolism, from IVIG therapy 1460
Thrombopoietin, for fetal alloimmune thrombocytopenia 1216
Thrombotic microangiopathy, BMT-associated 78
Thrombotic thrombocytopenic purpura
after cephalosporin 1317
BMT-associated 78
plasma exchange complications ..... 415(L)
platelet transfusion and ..... 829(L)
Tissue factor 177
Total body irradiation 241
Toxicology assessment, in transfusion medicine 1481
Tracking systems 556
Training, of transfusion medicine physicians 1344
Trak-C 958
TRALI. *See* Acute lung injury, transfusion-related
Transcription-mediated amplification 215, 1433
Transcription start site 656
Transfusion blood policy 1344
Transfusion medicine
in future 823
measuring scientific/medical practice progress 1344
Transfusion reactions 998
Transfusion sciences, in future 823
Transfusion service, communication with clinicians 1503
Transfusion support, for antibodies to high-frequency RBC antigens 1563
Transfusion-transmissible infections. *See also specific transmissible infections*
blood safety and S8:3
Chlamydia pneumoniae 552
CMV 1351
HBV DNA detection 696
of hepatitis A from single donation 536
HIV, prevalence in blood donors in Thailand 731
prevalence by donation site 705
risk in NAT-negative blood ..... 830(L)
spongiform encephalopathy 1687, 1694, 1706
viral 165, 848
West Nile virus 992, 1007
younger donors and 1596
Transfusion-Transmitted Viruses Study 1433
Trehalose, for cord blood cryopreservation 265
Trial to Reduce Alloimmunization to Platelets (TRAP) 1545
Trypanosoma cruzi recombinant antigens 91
TTP-HUS, plasma exchange complications ..... 415(L)

U

U antigen 1739, 1743, 1745, 1747
Umbilical cord blood. *See* Cord blood
Umbilical cord clamping, immediate *vs.* delayed 1168
Uncontrolled-rate freezing 42
United States
blood supply monitoring 364
military blood banking 1622
volunteer blood donation program crisis 273
Unreported deferrable risk 7, 1075, 1596
UVB irradiation
alloantibody production, regulation of 1295
immune response and 576

V

Vasovagal reactions
after whole-blood donation 598
body weight and 1084
Viability of platelets, after storage 857
Viral Activation Transfusion Study 98, 451, 1351
Viral marker screening assays 202
Viruses. *See also specific viruses*
inactivation 568
load in healthy adult donors 85
prev alence by blood donation site 705
transmission via transfusion 992, S8:3
Visual risk communication tool, evaluation of 779
Vitamin D 1403
Vitamin K-dependent coagulation factors 873
Vomiting, in donors 598
Von Willebrand disease 1514
VWF antigen 563, 1238

W

Waldenstrom's macroglobulinemia 989
War, blood use during 1622
Warm autoantibodies 651, 1503
WBC reduction
ABT mortality and 963
blood safety and S8:3
CMV activation 1351
collection of 1695, 1698, 1700, 1704
in cryopreserved RBC units 517
effect on frozen PLTs 1162
hepatitis A transmission 536
HLA and RBC immunization after 765
in-line whole-blood filter 1723
RBC adherence to vascular endothelia and 151
RBC alloimmunization and 945
residual WBC subsets after filtration 98
seven-day PLT concentrate storage 1374
single-donor PLTs 1107
universal ..... 831(L)
vs. methylene blue photoactivation of FFP 1238
WBC subsets, in filtered RBCs 98
West Nile virus
estimating risk of transmission 1007
transfusion-transmitted 992, 1018
verification studies 1023

Whole-blood donation
adverse effects in donors 598
cost-effectiveness of NAT 721
telomere length of PBLs 1089
Whole-blood filtration 395, 1723
Women, reduction of blood donation-related symptoms 1269
Wr^a antibodies 939

X

XK gene mutations 928
X-ray radiation, blood cell rheology and 502

Y

Yersinia enterocolitica, outgrowth prevention 135